Fig. 2From: Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida speciesTornado sensitivity analysis of anidulafungin vs. fluconazole for Candidemia/invasive candidiasis (x axis presents values of incremental cost-effectiveness ratio; ICER, incremental cost per life-year gained. Cost value is presented in 2015 US dollar)Back to article page